



## Immune-Inflammatory Modulation as the Therapeutic Strategy of Stem Cell Therapy for Amyotrophic Lateral Sclerosis

Seung Hyun Kim\*

Department of Neurology, Hanyang University, Republic of Korea

### Editorial

Amyotrophic Lateral Sclerosis (ALS) is a devastating neurodegenerative disease with no cure. The recent breakthroughs in pathogenic mechanisms of ALS and neurodegenerative diseases are summarized as follows: 1) Novel causative or associated genes not only expand the concepts on spectral paradigm of ALS from motor neuron disease to motor neural network syndrome or multisystem proteinopathy, but also emphasize the importance of RNA dysregulation and abnormal proteinostasis in neuronal death mechanisms [1-4]. 2) Importance of non-cell autonomous toxicity in neuronal cell death mechanisms in neurodegenerative disease [5,6]. 3) And diverse clinical study showing heterogeneity related with genetic backgrounds and multifactorial environmental factors [2].

Despite of all the advances in understanding the connection of clinical heterogeneity, genetic and molecular mechanisms of motor neuronal death in ALS, previously conducted clinical trials have failed. Most trials have been focused on single molecular target and not aiming multiple targets related to complex cell death mechanisms which could explain the failure of most clinical trials.

When focusing immune-inflammatory aspects in cell death mechanism of ALS, balance between pro-inflammatory and anti-inflammatory cytokines are not only important in onset but also disease progressive speed [7,8]. As shown in Figure 1, Proinflammatory cytokines including CCL2, IL-1 beta, CXCL10 are linearly increased as time is progressed from asymptomatic stage to advanced stage. However, anti-inflammatory cytokines such as TGF-beta, IL-4 and IL-10 are increased maximally to the time point of symptom onset, after that time point, these cytokines are rapidly dropped. And, the concepts on immune-inflammatory modulation are also accepted in other neurodegenerative diseases including Alzheimer and Parkinson disease. In molecular level, T-regulatory cell population number and dendritic transcriptional level have been characterized as a good biological marker for predicting progressive speed in ALS. In addition, activated subtype of microglia has been reported to be relevant in predicting disease progression [8,9].

Recently, mesenchymal stem cells (MSCs) therapy emerged as a potential therapeutic strategy for ALS and neurodegenerative disease because of having diverse effects. In addition to paracrine effects of MSCs releasing neurotrophic factors and stimulatory effect on intrinsic neurogenesis, MSCs are also known to regulate both innate and adaptive immune cells, through the release of soluble factors such as Prostaglandin E2 (PGE2), Indoleamine 2,3-dioxygenase (IDO), and TGF- $\beta$ , resulting in switching patient's environment from a proinflammatory toxic to an anti-inflammatory, and neuroprotective condition [10,11].

In preclinical study, intrathecally delivered human MSCs into cerebrospinal fluid of SOD1G93A mice slowed disease progression in relation to increased lymphocyte infiltration into the spinal cord [12]. And, when MSCs are cultured along with peripheral blood mononuclear cells (PBMC) derived from ALS patients increased significantly proportion of regulatory T cells (Treg) and Th2 cells with enhanced production of anti-inflammatory cytokines including IL-4, IL-10 and transforming growth factor-beta (TGF- $\beta$ ) [11].

We reported immuno regulatory mechanisms for MSCs, such as elevation of regulatory T cells (Tregs) and T helper-2 cells (Th2 cells), play important roles in neuroprotective effect on motor neuronal cell death mechanisms in ALS, with secretion of neurotrophic factors, crucial aspects for the effectiveness of MSCs in ALS [10,11]. In addition, MSCs can modulate the functional properties of microglia via TGF- $\beta$  secretion, switching roles from a classically activated phenotype to an

### OPEN ACCESS

#### \*Correspondence:

Seung Hyun Kim, Department of Neurology, Hanyang University, 222-1, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Republic of Korea, Tel: +82-2-2290-8371; Fax: +82-2-2296-8370;

E-mail: kimsh1@hanyang.ac.kr

Received Date: 17 Oct 2017


Accepted Date: 14 Nov 2017

Published Date: 20 Nov 2017


#### Citation:

Kim SH. Immune-Inflammatory Modulation as the Therapeutic Strategy of Stem Cell Therapy for Amyotrophic Lateral Sclerosis. *Ann Stem Cell Res Ther.* 2017; 1(1): 1002.

**Copyright** © 2017 Seung Hyun Kim. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



**Figure 1:** Temporal Patterns of Inflammatory Cytokine Level in ALS Tg Mice. Proinflammatory cytokines are linearly increased as time is progressed from asymptomatic stage to advanced stage. However, anti-inflammatory cytokines are reached at high level until symptom onset, after that these level are rapidly decreased.



**Figure 2:** Conceptual Hypothesis; Effect of Mesenchymal Stem Cells (MSCs) therapy in ALS; MSCs injected into cerebrospinal fluid space might change the pro-inflammatory environments into anti-inflammatory conditions, that is, converting Th1/M1 dominant environment into Th2 /Treg and M2 dominant condition.

inflammation-resolving phenotype. The role switching effect may be associated with the inhibition of neuroinflammatory processes in ALS [10]. Analyzing recent clinical trials, effect of MSCs on clinical response suggest strongly that properties of MSCs secreting VEGF, TGF-beta, and Angiogenin are related to good responders to MSC treatment. And when measuring the levels of CSF pro and anti-inflammatory cytokines after MSC treatment, IL-10, TGF-β and IL-6 levels were increased while monocyte chemo attractant protein 1 (MCP-1) levels decreased [13,14]. These findings suggest that immune-inflammatory modulation is an important therapeutic strategy for stem cell therapy for ALS, which is schematically summarized in Figure 2.

However these preclinical and clinical studies are still at preliminary stage, well designed clinical studies are essential with inclusion of post-hoc analysis and systematic analysis of reliable biological markers related to immune-inflammation. Recently published draft of guidelines for Clinical Trials in ALS/MND released from ALS Clinical Trials Workshop which took place at Airlie Conference in Warrenton, Virginia (March 2016) emphasized

the importance of excluding the genetic and clinical heterogeneity when enrolling subjects and requirements for post-hoc analysis on biological markers to identify subgroup of patients which appear to respond better to the specific treatment [15].

Therefore, more appropriate therapeutic strategies including optimal selection criteria of patients and quantitative measurement of reliable biological markers related immune-inflammatory cytokines would be important when evaluating the strategy of stem cell therapy aiming immune-inflammatory modulation.

**References**

1. Taylor JP, Brown RH, Cleveland DW. Decoding ALS: from genes to mechanism. *Nature*. 2016;539(7628):197-206.
2. Gao FB, Almeida S, Lopez-Gonzalez R. Dysregulated molecular pathways in amyotrophic lateral sclerosis-frontotemporal dementia spectrum disorder. *EMBO J*. 2017;36(20):2931-50.
3. Couratier P, Corcia P, Lattredde G, Nicol M, Marin B. ALS and frontotemporal dementia belong to a common disease spectrum. *Rev*

- Neurol. 2017;173(5):273-9.
4. Benatar M, Wu J, Fernandez C, Weihl CC, Katzen H, Steele J, et al. Motor neuron involvement in multisystem proteinopathy: implications for ALS. *Neurology*. 2013;80(20):1874-80.
  5. Boillée S, Vandervele C, Cleveland DW. ALS: a disease of motor neurons and their nonneuronal neighbors. *Neuron*. 2006;52(1):39-59.
  6. Ilieva H, Polymenidou M, Cleveland DW. Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond. *J Cell Biol*. 2009;187(6):761-72.
  7. Noh MY, Cho KA, Kim H, Kim SM, Kim SH. Erythropoietin modulates the immune-inflammatory response of a SOD1(G93A) transgenic mouse model of ALS. *Neurosci Lett*. 2014;574:53-8.
  8. Henkel JS, Engelhardt JI, Siklós L, Simpson EP, Kim SH, Pan T, et al. Presence of dendritic cells, MCP-1, and activated microglia/macrophages in amyotrophic lateral sclerosis spinal cord tissue. *Ann Neurol*. 2004;55(2):221-35.
  9. Henkel JS, Beers DR, Wen S, Rivera AL, Toennis KM, Appel JE, et al. Regulatory T-lymphocytes mediate amyotrophic lateral sclerosis progression and survival. *EMBO Mol Med*. 2013;5(1):64-79.
  10. Noh MY, Lim SM, Oh KW, Cho KA, Park J, Kim KS, et al. Mesenchymal stem cells modulate the functional properties of microglia via TGF-beta secretion. *Stem Cells Transl Med*. 2016;5(11):1538-49.
  11. Kwon MS, Noh MY, Oh KW, Cho KA, Kang BY, Kim KS, et al. The immunomodulatory effects of human mesenchymal stem cells on peripheral blood mononuclear cells in ALS patients. *J Neurochem*. 2014;131(2):206-18.
  12. Kim H, Kim HY, Choi MR, Hwang S, Nam KH, Kim HC, et al. Dose-dependent efficacy of ALS-human mesenchymal stem cells transplantation into cisterna magna in SOD1-G93A ALS mice. *Neurosci Lett*. 2010;468(3):190-4.
  13. Kim HY, Kim H, Oh KW, Oh SI, Koh SH, Baik W, et al. Biological markers of mesenchymal stromal cells as predictors of response to autologous stem cell transplantation in patients with amyotrophic lateral sclerosis: an investigator-initiated trial and in vivo study. *Stem Cells*. 2014;32(10):2724-31.
  14. Oh KW, Moon C, Kim HY, Oh SI, Park J, Lee JH, et al. Phase I trial of repeated intrathecal autologous bone marrow-derived mesenchymal stromal cells in amyotrophic lateral sclerosis. *Stem Cells Transl Med*. 2015;4(6):590-7.
  15. Guidance for Industry Drug Development for Amyotrophic Lateral Sclerosis; 2016.